Alleima (ALLEI) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
27 Apr, 2026Executive summary
Market uncertainty and geopolitical instability, especially in the Middle East, persisted, impacting customer investment and short-cycle business.
Key segments like medical and industrial heating (Kanthal) showed resilience and favorable performance, with strong organic order intake.
Efficiency measures and improved cost position began to yield positive effects, but could not fully offset negative currency impacts and lower sales.
Sustainability performance remained strong, with over 81% recycled steel and a record-high sustainable product portfolio at nearly 26%.
Strategic investments were completed in Industrial Heating and ongoing in Medical to support long-term growth.
Financial highlights
Order intake for the rolling 12 months was SEK 16,266 million, down 12% organically, mainly due to prior year major orders and OCTG declines.
Quarterly revenues reached SEK 4,576 million, a 5% organic decline year-over-year, with negative FX and alloy effects.
Adjusted EBIT was SEK 386 million (margin 8.4%), down from 10.5% last year, diluted by SEK -93 million currency effects.
Adjusted EPS for the quarter was SEK 1.14, negatively impacted by lower EBIT.
Free operating cash flow was SEK -65 million, reflecting lower EBITDA and working capital seasonality.
Outlook and guidance
Market instability and geopolitical uncertainty, especially from the Middle East, are expected to persist into Q2 2026, dampening investment and short-cycle business.
Solid backlog in umbilicals, oil and gas, industrial heating, medical, and nuclear segments provides near-term delivery visibility.
Full-year CapEx guidance remains at SEK 1,100 million, with Q1 spend at SEK 160 million.
Currency effects for Q2 estimated at SEK -60 million; positive metal price effect of SEK 150 million anticipated.
Normalized tax rate for 2026 expected in the 23%-25% range.
Latest events from Alleima
- Flat organic growth, strong cash flow, and improved EBIT amid robust market sentiment.ALLEI
Q2 20243 Feb 2026 - Flat 2025 revenue, strong cash flow, and SEK 2.50 dividend amid FX and market headwinds.ALLEI
Q4 20252 Feb 2026 - Organic revenue up 3%, EBIT margin 7%, with strong nuclear and medical investments.ALLEI
Q3 202419 Jan 2026 - Stable earnings, strong cash, and growth in key segments despite mixed market demand.ALLEI
Q4 20249 Jan 2026 - Strong Q1 growth and margins, but Q2 faces currency and metal price headwinds.ALLEI
Q1 202528 Dec 2025 - Profitability held up despite revenue declines and market uncertainty, with resilient margins.ALLEI
Q2 202516 Nov 2025 - Profitable growth, innovation, and sustainability drive expansion in high-value segments.ALLEI
CMD 20258 Nov 2025 - Flat revenues and lower margins amid weak demand, with cost-saving actions and strong backlogs.ALLEI
Q3 202523 Oct 2025